46 withdrawn. 46 Phase 1, 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 46 | Withdrawn 46 |
| Phase 2 | 14 | Withdrawn 14 |
Follow Leukemia, B-Cell: new trials by email Literature Review of Leukemia, B-Cell trials Research Report on Leukemia, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies anti-CD19 UCAR-NK cells - B-cell Lymphoma, B-cell Leukemia | Phase 1 / Phase 2 | Withdrawn | Kunming Hope of Health Hospital | 2022-10-01 | 2022-11-30 | |
| Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation Ibrutinib, Ipilimumab, Nivolumab - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2022-07-14 | 2025-02-28 | |
| Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma PACE CART19 - Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Withdrawn | University of Pennsylvania | 2022-07-01 | 2023-06-22 | |
| Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies CAR-NK-CD19 Cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Withdrawn | Beijing Boren Hospital | 2022-05-10 | 2026-10-15 | |
| Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL JWCAR029 (Relmacabtagene Autoleucel) - Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Withdrawn | Shanghai Ming Ju Biotechnology Co., Ltd. | 2022-02-28 | 2023-11-24 | |
| HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL HMPL-760 - CLL/SLL, NHL | Phase 1 | Withdrawn | Hutchmed | 2022-02-15 | 2023-02-21 | |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL CpG-STAT3 siRNA CAS3/SS3, Radiation Therapy - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2021-07-27 | 2024-04-25 | |
| Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL Dose combination 1-1, dose combination 1-2, Dose combination 1-3 - Chronic Lymphocytic Leukemia, CLL | Phase 1 | Withdrawn | Virginia Commonwealth University | 2020-10-02 | 2021-11-09 | |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies Ibrutinib, LY3214996 - Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia | Phase 1 | Withdrawn | Dana-Farber Cancer Institute | 2020-02-03 | 2020-02-05 | |
| Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Rivogenlecleucel, Rimiducid - Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2020-01-02 | 2020-08-14 | |
| Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor Trabectedin, Venetoclax - Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2019-06-18 | 2023-09-25 | |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-05-15 | 2023-08-21 | |
| Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma Blinatumomab, Pembrolizumab - Leukemia, B-cell, Lymphoma, B-Cell | Phase 1 | Withdrawn | Children's Hospital Medical Center, Cincinnati | 2018-09-27 | 2021-04-01 | |
| This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax Venetoclax, BI 836826 - Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Withdrawn | Boehringer Ingelheim | 2018-01-17 | 2018-01-09 | |
| Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies 4SCAR19/22 T cells, Interleukin-2 - B-Cell Leukemia, B-Cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | Zhujiang Hospital | 2017-12-30 | 2024-03-18 | |
| Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02) Betalutin with lilotomab dose 1, Betalutin with lilotomab dose 2 - Non-Hodgkin Lymphoma | Phase 1 | Withdrawn | Nordic Nanovector | 2017-12-19 | 2019-01-10 | |
| Safety and Activity of SNX-5422 Plus Ibrutinib in CLL SNX-5422 plus ibrutinib - Cancer | Phase 1 | Withdrawn | Esanex Inc. | 2017-02-02 | 2018-07-30 | |
| Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Pacritinib, Ibrutinib - Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic | Phase 1 / Phase 2 | Withdrawn | University of Michigan Rogel Cancer Center | 2016-10-01 | 2017-09-06 | |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma Duvortuxizumab, Ibrutinib - Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse | Phase 1 | Withdrawn | Janssen Research & Development, LLC | 2016-07-20 | 2025-02-03 |
Showing 20 of 46. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (43) · Lymphoma, Mantle-Cell (17) · Lymphoma, Non-Hodgkin (16) · Leukemia (15) · Lymphoma, Follicular (15) · Lymphoma, B-Cell, Marginal Zone (14) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Lymphoma, Large B-Cell, Diffuse (12) · Lymphoma (10) · Burkitt Lymphoma (8) · Leukemia, Myeloid, Acute (8) · Lymphoma, Large-Cell, Immunoblastic (7) · Myelodysplastic Syndromes (6) · Neoplasms (6) · Waldenstrom Macroglobulinemia (6)
Hematologic Diseases (46) · Hemic and Lymphatic Diseases (46) · Immunoproliferative Disorders (46) · Immune System Diseases (45) · Leukemia, Lymphoid (45) · Lymphatic Diseases (45) · Neoplasms by Histologic Type (45) · Disease Attributes (44) · Pathologic Processes (44) · Pathological Conditions, Signs and Symptoms (44) · Chronic Disease (43) · Lymphoproliferative Disorders (43) · Neoplasms (40) · Leukemia (31)
ibrutinib (6) · Cyclophosphamide (5) · fludarabine phosphate (5) · fludarabine (4) · Cyclosporine (3) · Peripheral Blood Stem Cell Transplantation (3) · venetoclax (3) · Bendamustine Hydrochloride (2) · Dasatinib (2) · Flow Cytometry (2) · In Situ Hybridization, Fluorescence (2) · Interleukin-2 (2) · Lenalidomide (2) · Mycophenolic Acid (2) · Radiotherapy (2)
M.D. Anderson Cancer Center (9) · Bristol-Myers Squibb (2) · Fred Hutchinson Cancer Center (2) · AbbVie (1) · Afexa Life Sciences Inc (1) · Alliance for Clinical Trials in Oncology (1) · Barbara Ann Karmanos Cancer Institute (1) · Baylor College of Medicine (1) · Beijing Boren Hospital (1) · Boehringer Ingelheim (1) · Children's Hospital Medical Center, Cincinnati (1) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · Esanex Inc. (1) · GlaxoSmithKline (1)
United States (17) · China (4) · Australia (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Poland (1) · Spain (1)
Amar Safdar, MD (1) · Andreas Buck, Prof. MD (1) · Apostolia M. Tsimberidou, MD, PHD (1) · Asher Chanan-Khan (1) · Christos E. Emmanouilides, MD (1) · Claudio Brunstein, MD, PhD (1) · Darren Sigal, MD (1) · David Valacer, MD (1) · Elizabeth Krakow (1) · Erin Breese, MD. PhD (1) · Grzegorz Nowakowski (1) · H. Joachim Deeg, MD (1)
PMID 18003886, PMID 20408846, PMID 24443277
P30CA016672 (2), 2014 (1), 2015 (1), 2016 (1), P30CA015083 (1), P30CA015704 (1), P30CA022453 (1), P30CA033572 (1), P30CA036727 (1), P50CA107399 (1)